Effects of neoadjuvant immunotherapy on hearing in patients with head and neck squamous cell carcinoma

Effects of neoadjuvant immunotherapy on hearing in patients with head and neck squamous cell carcinoma

Abstract Immune checkpoint blockade (ICB) is a commonly used treatment modality for cancer with a growing list of oncologic indications. Ototoxicity is a potential immune-related adverse event of ICB treatment, but the risk of hearing loss after ICB remains unknown. This retrospective chart review s...

Full description

Saved in:
Bibliographic Details
Main Authors: Bryce Hambach, Anhelina Bilokon, John Lee, L. Noelle Allemang, Jennifer Chisholm, Chris K. Zalewski, Julie Christensen, Carmen C. Brewer, James L. Gulley, Clint T. Allen, Lisa L. Cunningham, Katharine A. Fernandez
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Immune checkpoint blockade (ICB)
Neoadjuvant therapy
Hearing loss
Head and neck cancer
Ototoxicity
Long-term monitoring
Online Access:https://doi.org/10.1038/s41598-025-13706-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-13706-9

Similar Items